DBV Technologies (FR:DBV)
:DBV
DBV Stock Chart & Stats
€3.53
€0.10(13.73%)
At close: 4:00 PM EST
€3.53
€0.10(13.73%)
Day’s Range― - ―
52-Week Range€1.20 - €4.50
Previous CloseN/A
Volume1.76M
Average Volume (3M)1.12M
Market Cap
€981.81M
Enterprise Value€523.97M
Total Cash (Recent Filing)€194.19M
Total Debt (Recent Filing)€21.69M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 04, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding278,352,080
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.50Price Target Upside55.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€4.10M
Bulls Say, Bears Say
Bulls Say
Successful Phase 3 DataA positive Phase 3 readout materially strengthens the clinical case for Viaskin Peanut and validates DBV’s EPIT approach. This reduces binary clinical risk, improves prospects for regulatory approval and commercialization, and supports future partnerships or licensing opportunities.
Proprietary EPIT PlatformDBV’s EPIT patch is a differentiated delivery platform for allergy immunotherapy. If clinically validated, it offers a durable competitive advantage through unique mechanism, potential multi-allergy applications, recurring patch revenues, and higher barriers to replication by competitors.
Modest LeverageLow reported leverage provides financial flexibility versus highly leveraged peers, lowering near-term interest burdens and preserving capacity to raise equity or debt to fund commercialization and trials. It meaningfully moderates immediate solvency risk while losses persist.
Bears Say
High Cash BurnSustained ~-$122M TTM free cash flow indicates material funding needs. Persistent cash burn forces repeated financing, increasing dilution risk and distracting management with capital raises. Absent meaningful revenue ramp, spending cuts or large financing, runway and execution risk remain elevated.
Weak Revenue And Negative Gross ProfitDeclining, small revenues and negative gross profit show the company lacks scalable commercial throughput and has an unfavorable cost structure. This undermines near-term self-funding, delays margin recovery, and raises the burden on product launches to quickly generate sustainable unit economics.
Large Ongoing Losses; Financing RiskDeep operating and net losses create persistent dilution and sensitivity to capital raises. Equity swings in prior years suggest funding has materially affected capital structure; until profitability or sustained revenue emerges, the company remains exposed to financing availability and timing risks.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.20 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €981.81M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is May 04, 2026 which is in 26 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Mar 26, 2026. The company reported -€0.042 earnings per share for the quarter, missing the consensus estimate of -€0.03 by -€0.012.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Undervalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 278,352,080 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.042 in its last earnings report, missing expectations of -€0.03. Following the earnings report the stock price went up 0.283%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
DBV Stock 12 Month Forecast
Average Price Target
€5.50
▲(55.81% Upside)
Technical Analysis
Options Prices
Currently, No data available
---